Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
NEW YORK, Feb. 11, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Tetraphase Pharmaceuticals Inc. (“Tetraphase”) (NASDAQ:TTPH) between March 5, 2015 and September 8, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://zlk.9nl.com/tetraphase-pharmaceuticals-ttph
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
